Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first‐line therapy for patients with advanced NSCLC harboring activating EGFR mutation.3 This evidence concerns the gene EGFR and non-small cell lung carcinoma.